Replies to post #12314 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

I agree that Dr. Moro traveling is about RECAF and my guess would be to reach an agreement in principle. We might have the signing of a third licensee within a couple of months. That would sure fit in with paying cash on the loan if that deal includes significant up front cash.

[HALF FULL GLASS]

Opportunity, I like this part!

January/February 2008
A new biomarker may have the potential to help mammography identify malignant versus benign breast lesions. RECAF (Receptor of Alpha Fetoprotein) has been found in over 90 percent of the breast cancers studied to date, according to BioCurex. The marker is present on the surface and within cancer cells, as well as in the blood of cancer patients.

According to the researcher who discovered the RECAF marker, Ricardo Moro-Vidal, M.D., CEO and president, the company is gearing up to begin a clinical trial with a leading institution to determine if a blood test can help radiologists better anticipate if a lesion is benign or malignant. In a malignant tumor, the levels of RECAF circulation within the blood increase. “If we can obtain 93 percent sensitivity and specificity, then we can potentially help reduce the number of false positives that lead to unnecessary breast biopsies,” he said. <

Being that most of this article is about Siemens...I wonder if this is the leading institution? Or maybe Abbott??

[was Gyro]

Good finds - seems like real coverage more so than the "Shazaam" hype coverage that has been the norm. The second link you posted mentions the deal between IMA and Biocurex, but I was bummed that in the very next paragraph when they were talking about Abbott, they didn't mention its license with Biocurex. I suppose the article is just about new activity, so the ABT deal doesn't count.

[doggone01]

Great to hear from you.Glad you didnt jump ship,nice writeups thankyou!Look forward to hearing more from ya in the furture!!!